Search research articles
Contact Us
Filters
Showing results (141-150 of 150) with videos related to
Page
of 15
Sort By:
You have reached the last page of results.
This site can display upto 150 results.
Blood
|
August 24, 2007
MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts
Sonia Vallet, Noopur Raje, Kenji Ishitsuka, et al.
Cancer Research
|
September 4, 2012
GF-15, a novel inhibitor of centrosomal clustering, suppresses tumor cell growth in vitro and in vivo
Marc S Raab, Iris Breitkreutz, Simon Anderhub, et al.
Leukemia
|
September 7, 2021
Publisher Correction: JunB is a key regulator of multiple myeloma bone marrow angiogenesis
Fengjuan Fan, Stefano Malvestiti, Sonia Vallet, et al.
Leukemia
|
May 19, 2021
JunB is a key regulator of multiple myeloma bone marrow angiogenesis
Fengjuan Fan, Stefano Malvestiti, Sonia Vallet, et al.
British Journal of Cancer
|
June 5, 2021
Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM)
Moshe Lapidot, Abigail E Case, Ellen L Weisberg, et al.
Ejhaem
|
June 19, 2024
QoL during KTd or KRd induction followed by K maintenance or observation in transplant noneligible patients with newly diagnosed multiple myeloma: Longitudinal and cross-sectional analysis of the randomized AGMT 02 study
Heinz Ludwig, Thomas Melchardt, Ilvy Schweitzer, et al.
American Journal of Hematology
|
March 1, 2024
Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma
Heinz Ludwig, Thomas Melchardt, Siegfried Sormann, et al.
Blood
|
October 2, 2007
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu
Yu-Tzu Tai, Myles Dillon, Weihua Song, et al.
BMC Cancer
|
September 7, 2021
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
Gabriel Tremblay, Patrick Daniele, Janis Breeze, et al.
The New England Journal of Medicine
|
August 22, 2019
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma
Ajai Chari, Dan T Vogl, Maria Gavriatopoulou, et al.
Page
of 15
Search research articles
Search
Showing results (141-150 of 150) with videos related to
Sort By:
Page
of 15
You have reached the last page of results.
This site can display upto 150 results.
Blood
|
August 24, 2007
MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts
Sonia Vallet, Noopur Raje, Kenji Ishitsuka, et al.
Cancer Research
|
September 4, 2012
GF-15, a novel inhibitor of centrosomal clustering, suppresses tumor cell growth in vitro and in vivo
Marc S Raab, Iris Breitkreutz, Simon Anderhub, et al.
Leukemia
|
September 7, 2021
Publisher Correction: JunB is a key regulator of multiple myeloma bone marrow angiogenesis
Fengjuan Fan, Stefano Malvestiti, Sonia Vallet, et al.
Leukemia
|
May 19, 2021
JunB is a key regulator of multiple myeloma bone marrow angiogenesis
Fengjuan Fan, Stefano Malvestiti, Sonia Vallet, et al.
British Journal of Cancer
|
June 5, 2021
Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM)
Moshe Lapidot, Abigail E Case, Ellen L Weisberg, et al.
Ejhaem
|
June 19, 2024
QoL during KTd or KRd induction followed by K maintenance or observation in transplant noneligible patients with newly diagnosed multiple myeloma: Longitudinal and cross-sectional analysis of the randomized AGMT 02 study
Heinz Ludwig, Thomas Melchardt, Ilvy Schweitzer, et al.
American Journal of Hematology
|
March 1, 2024
Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma
Heinz Ludwig, Thomas Melchardt, Siegfried Sormann, et al.
Blood
|
October 2, 2007
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu
Yu-Tzu Tai, Myles Dillon, Weihua Song, et al.
BMC Cancer
|
September 7, 2021
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
Gabriel Tremblay, Patrick Daniele, Janis Breeze, et al.
The New England Journal of Medicine
|
August 22, 2019
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma
Ajai Chari, Dan T Vogl, Maria Gavriatopoulou, et al.
Page
of 15